tbuckley/cabot-search huggingface dataset:
Measurements of 24-Hour Urinary Sodium and Potassium Excretion
Authors: Joachim H. Ix, Cheryl A. M. Anderson
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Free wi-fi could tackle the 70% of junior doctors’ time spent on admin, says online entrepreneur
Authors: Abi Rimmer
Journal: BMJ (2015)

Junior doctors spend 70% of their time on administrative tasks that could be reduced by introducing free wi-fi in the NHS, an online entrepreneur has said.

Martha Lane Fox, cofounder of lastminute.com, said in a letter to the health secretary, Jeremy Hunt, that free access to wi-fi networks would free up “more time for patient care.” …
Vascular Malformations and Health-Related Quality of Life
Authors: Henry L. Nguyen, George F. Bonadurer, Megha M. Tollefson
Journal: JAMA Dermatology (2018)

<h3>Importance</h3> Patients with vascular malformations (VAMs) and vascular overgrowth syndromes have lower health-related quality of life (HRQoL) attributable to social stigmatization, poor mental health, severity, and pain. However, the factors that contribute to this decreased HRQoL are not clear. <h3>Objective</h3> To perform a systematic review and meta-analysis of studies that used validated HRQoL instruments to compare the HRQoL of persons with VAMs with the US general population. <h3>Data Sources</h3> A comprehensive search was performed in MEDLINE, Embase, PsycINFO, CINAHL, and Scopus from 1946 to March 31, 2017, with the consultation of an experienced librarian. <h3>Study Selection</h3> All VAM studies with validated HRQoL instruments published in the English language were included. Case reports, review articles, non–English-language publications, and studies about the development of new HRQoL instruments were not included. <h3>Data Extraction and Synthesis</h3> Two reviewers assessed studies' eligibility and the risk of bias and performed data extraction. The meta-analysis was performed using the random-effects model. Comparisons of means were performed using the unpaired, 2-sample<i>t</i>test. <h3>Main Outcomes and Measures</h3> The outcome was HRQoL. <h3>Results</h3> Eleven studies met the inclusion criteria for a total of 692 patients with VAMs. Six studies (320 patients) were included in the meta-analysis, whereas 5 studies were included in the qualitative analysis (372 patients). Those with VAMs had lower 36-Item Short-Form Health Survey scores in bodily pain (mean difference, −11.87; 95% CI, −21.45 to −2.29;<i>I</i><sup>2</sup> = 92%;<i>P</i> = .02) and mental health (mean difference, −6.04; 95% CI, −11.55 to −0.52;<i>I</i><sup>2</sup> = 83%;<i>P</i> = .03) compared with the US general population. <h3>Conclusions and Relevance</h3> Patients with VAMs had increased pain and psychosocial distress compared with the US general population. Pain and psychological morbidity are associated with poorer HRQoL and may serve as indicators for quality of life.
PREVALENCE OF NEOATHEROSCLEROSIS IN SIROLIMUS-ELUTING STENTS AT VERY LATE PHASE FROM IMPLANTATION
Authors: Eisuke Usui, Taishi Yonetsu, Yoshinori Kanno, Rikuta Hamaya, Tadashi Fukuda, Hiroaki Ohya, Yohei Sumino, Masahiro Hada, Masao Yamaguchi, Masahiro Hoshino, Yoshihisa Kanaji, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2018)
NONBACTERIAL THROMBOTIC ENDOCARDITIS DESPITE ANTICOAGULATION WITH NEW ORAL ANTICOAGULANTS
Authors: Ioana Petrescu, Htin Aung, Filip Ionescu, Waldemar Wysokinski, Vuyisile Nkomo, Joseph Maleszewski, Meissner Irene, Lawrence Sinak, Sorin Pislaru
Journal: Journal of the American College of Cardiology (2018)
EFFECTS OF IVABRADINE ON SYMPATHETIC OVERDRIVE AND ARTERIAL STIFFENING IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME: A 6 MONTH FOLLOW-UP STUDY
Authors: Konstantinos P. Tsioufis, Kyriakos Dimitriadis, Evaggelia Koutra, Theodoros Kalos, Christos Fragoulis, Lefki Nikolopoulou, Dimitris Konstantinidis, Areti Koumelli, Konstantinos Konstantinou, Ioanna Karapati, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2018)
The role of temporal artery biopsy in patients with giant-cell arteritis is debated
Authors: Sergey V Moiseev, Ilya Smitienko, Nikolay Bulanov, Pavel I Novikov
Journal: Annals of the Rheumatic Diseases (2018)

Over a few decades, temporal artery biopsy (TAB) was regarded as the gold standard for diagnosis of giant-cell arteritis (GCA). However, is it really necessary to use this invasive test in all patients with GCA, particularly in those with typical clinical features of the disease? Can we replace TAB with imaging modalities, including ultrasound and [18F]-fluorodeoxyglucose positron emission tomography (PET), that are more sensitive and/or more readily available in many institutions? Dejaco et al said yes in the recently published European League Against Rheumatism recommendations for the use of imaging in large-vessel vasculitis in clinical practice.1 The authors suggested that in patients in whom there is a high clinical suspicion of GCA and a positive ultrasound, the diagnosis of GCA may be made without biopsy or further imaging. Other imaging modalities, that is, PET and/or MRI, are more valuable in patients with Takayasu-like GCA without cranial signs and symptoms. Noteworthy, the task force clearly emphasised that TAB should be performed in all cases, where GCA cannot be confirmed or excluded based on clinical, laboratory and imaging results. Moreover, TAB should still be a …
CetuGEX and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): PK/PD results from the phase II RESGEX study.
Authors: Hans Baumeister, Alfredo Zurlo, Jerome Fayette, Bruno Dietrich, Ulrich Keilholz
Journal: Journal of Clinical Oncology (2018)

61 Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU (F), and the EGFR blocking monoclonal antibody (mAb) cetuximab (C). The mAb CetuGEX (CG) shares with cetuximab the identical EGFR-binding domain, but harbors a defucosylated glycan at the Fc part to increase antibody dependent cellular cytotoxicity (ADCC) by improved binding at the Fcγ receptors IIIa (FcγRIIIa). Methods: 240 pts with RM-HNSCC were randomized in 34 European centers, of which 123 received C and 117 CG, in combination with P (100 mg/m 2 ) and F (4 x 1000 mg/m 2 /24hrs) for the first 6 cycles. Initial dose of C was 400mg/m 2 , followed by weekly 250 mg/m 2 . CG was administered once 990 mg, followed by weekly infusions of 720 mg. After completion of combination treatment, pts received single agent mAb maintenance until disease progression or intolerable toxicity. The tumor tissues were analyzed for EGFR and p16 expression by IHC staining. Blood samples were withdrawn to analyze the FcγRIIIa phenotypes V/V, V/F and F/F and the FcγRIIa phenotypes R/R, H/R and R/R of each patient. The cellular immune status was analyzed in a subset of about 20 pts per arm before 1 st and 5 th infusion and 28 days after last infusion (Safety Visit) by flow cytometry. Serum CG concentrations were measured before and after the first ten infusions and for a subset of about 20 pts 5 h, 7 h, 24 h, 48 h, 72 h, and 168 h after the first and 10 th infusion. The occurrence of anti-drug antibodies (ADA) was determined before 1 st , 2 nd , 4 th and 10 th infusion of CG and at the Safety Visit. Efficacy and safety parameters will be looked at in relation to the biomarkers. Results: While most analyses did not show any difference between CG and C, the subgroup of p16 + pts (N=32) is characterized by a significantly longer overall survival (HR 0.52; 95%-CI 0.29 – 0.86; p=0.009) than that of p16 - pts, which remains significant under CG (17 pts; HR 0.43; 95%-CI 0.18 – 0.88; p=0.02) but not C treatment (15 pts), probably due to differences in pts immune status. Conclusion: The RESGEX study is the first head-to-head comparison of an ADCC-optimized to a conventional anti-EGFR mAb. The biomarker assessment may help to understand differences between the two mAbs. Clinical trial information: NCT02052960.
Macular Degeneration: Wet-AMD on a Chip: Modeling Outer Blood-Retinal Barrier In Vitro (Adv. Healthcare Mater. 2/2018)
Authors: Minhwan Chung, Somin Lee, Byung Joo Lee, Kyungmin Son, Noo Li Jeon, Jeong Hun Kim
Journal: Advanced Healthcare Materials (2018)

In article number 1700028, Noo Li Jeon, Jeong Hun Kim, and co-workers describe a unique organotypic eye-on-a-chip model that mimics the retinal pigment epithelium (RPE)–choroid complex in vitro. This model consists of an RPE monolayer and adjacent perfusable blood vessel network, which is supporting barrier function of the outer blood retinal barrier (oBRB). The intact barrier function of the RPE-choroid complex is reconstituted while maintaining important structural features.
First cardiothoracic surgical workshop in UK for medical students and junior doctors
Authors: Kok Hooi Yap, Shaza Mohamed, Charlotte Li, Timothy Strang, Rajamiyer Venkateswaran, Rajesh Shah
Journal: BMJ (2012)

Kok Hooi Yap and colleagues describe their experiences in setting up a cardiothoracic workshop to increase interest in the specialty among medical students and junior doctors
The Problem of Burnout Among Surgeons
Authors: Marco G. Patti, Francisco Schlottmann, Michael G. Sarr
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
New models to study vascular mural cell embryonic origin: implications in vascular diseases
Authors: Sanjay Sinha, Massimo Mattia Santoro
Journal: Cardiovascular Research (2018)

A key question in vascular biology is how the diversity of origin of vascular mural cells, namely smooth muscle cells (SMCs) and pericytes influences vessel properties, in particular the regional propensity to vascular diseases. This review therefore first describes the role and regulation of mural cells during vascular formation, with a focus on embryonic origin. We then consider the evidence that connects heterogeneities in SMC and pericyte origins with disease. Since this idea has major implications for understanding and modelling human disease, then there is a pressing need for new model systems to investigate mural cell development and the consequences of heterogeneity. Recent advances arising from in vitro strategies for deriving mural cells from human pluripotent stem cells as well as from the zebrafish model will be discussed and the medical relevance of these discoveries will be highlighted.
Clinical and histologic features of Mycoplasma pneumoniae –related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes
Authors: Reyhan Amode, Saskia Ingen-Housz-Oro, Nicolas Ortonne, Touda Bounfour, Sabine Pereyre, Frédéric Schlemmer, Emilie Bequignon, Gérard Royer, Pierre Wolkenstein, Olivier Chosidow
Journal: Journal of the American Academy of Dermatology (2018)
Foundation programme oversubscription is higher than in previous years
Authors: Helen Jaques
Journal: BMJ (2013)

The level of oversubscription to the 2013 foundation programme is higher than in previous years, although the exact number of applicants can’t yet be confirmed, the UK Foundation Programme Office has said. Nevertheless the health minister Dan Poulter has committed the government to guaranteeing all graduates of UK medical schools a place on a foundation training programme in 2013.

In October …
Use of immune checkpoint inhibitors in a community practice within a vertically integrated health care system.
Authors: Robert Michael Cooper, Christopher Yamamoto, Thach-Giao Truong, Fang Niu, Helen Moon, Michele M. Spence, Jim Chan, Timothy Chiu, Rita L. Hui
Journal: Journal of Clinical Oncology (2018)

130 Background: Four immune checkpoint inhibitors have been FDA approved from 2011 to 2016. Immune checkpoint inhibitors function differently from chemotherapy and have different benchmarks for response as well as different side effect profiles. This report examines how oncologists in two large medical groups have introduced these new treatments into their practices. Kaiser Permanente is a large HMO which insures 8.5 million members in the state of California and has an exclusive contract with 2 large medical groups to care for its members. There are over 200 medical oncologists caring for KP members practice at over 35 medical centers. The care of the KP members has been documented in an EPIC based medical record systems since 2006. Methods: The Pharmacy Research Outcomes Group has conducted a retrospective cohort study looking at patients who initiated Checkpoint inhibitors between March 2011 and September 2016 for this review and followed the patients till December 2016. Electronically available data collected for this review includes patient characteristics such as but not exclusive to: cancer diagnosis, previous therapies, current therapies, age, sex, ethnicity, immune related adverse events (IRAEs) proxy by diagnosis code, duration of immunotherapy, use of systemic steroids, Charlson Co-morbity Index and survival. Results: We reviewed a total of 1760 users of Checkpoint Inhibitors. We show the uptake of this class of medications aligns with approved checkpoint inhibitors and the new indications of these agents. We were able to electronically pull medical information and define IRAEs. Our data closely matches the expected incidence of IRAEs as reported in clinical trials. We were also able to monitor the use of steroids in response to these events. Conclusions: The ability to collect and track this information has allowed the group to better understand patient selection practices as well as management practices in the community practice setting.
Nearly half of GPs think patients have become more violent, survey finds
Authors: Abi Rimmer
Journal: BMJ (2015)

Nearly half of GPs believe patients to be more violent or aggressive than they were five years ago, a survey carried out by the Medical Protection Society has found.

The survey of 254 GPs found that 46% believed that patients were more violent and aggressive than five years ago, while 35% thought that levels of violent and aggressive behaviour had remained …
Does the exact result that you get in the PLAB exam, for example, 129 or 150 or 160, make any difference when you are looking for jobs?
Authors: Adekunle Olowu
Journal: BMJ (2004)

Got a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone (www.bmjcareers.com/advicezone) for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site.
Cortical Thinning and Neuropsychiatric Outcomes in Children Exposed to Prenatal Adversity: A Role for Placental CRH?
Authors: Curt A. Sandman, Megan M. Curran, Elysia Poggi Davis, Laura M. Glynn, Kevin Head, Tallie Z. Baram
Journal: American Journal of Psychiatry (2018)

The authors sought to assess associations among early-life exposure to adversity, the development and maturation of neurons and brain circuits, and neurodevelopmental outcomes. Specifically, they examined whether fetal exposure to placental corticotropin-releasing hormone (CRH), a molecule conveying maternal signals to the fetus, predicts brain growth and neuropsychiatric outcomes in school-age children.
Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
Authors: Muthalagu Ramanathan, Jan Cerny, Glen Raffel, William Vincent Walsh, Bruce Woda, Patricia Miron, Rajneesh Nath
Journal: Journal of Clinical Oncology (2012)

6569 Background: Induction chemotherapy is often not used in elderly patients with AML due to poor prognosis and inferior outcomes. We present here our experience in treating 20 patients age&gt;70yrs with an induction regimen consisting of high dose cytarabine and mitoxantrone (HiDAC/MITO). Methods: We analyzed all patients age &gt; 70 years who underwent induction with HiDAC/MITO at our institution from January 2009 to December 2011. 20 patients received HiDAC at 3 g/m2 daily on days 1-5 and mitoxantrone 80mg/m2* once on day 2(*one patient received 60mg/m2). The end points analyzed were complete remission (CR) and induction mortality at day 30, overall survival and progression free survival. Results: Median age was 75 years (70-83). 11 (55%) patients were male and 9 (45%) patients were female. Median duration of follow up of 10 (50%) patients who are still alive at the time of this analysis is 439 days (38-1095). High risk cytogenetics was noted in 11 (55%) patients including two patients with FLT3 mutated cytogenetics. Intermediate risk cytogenetics was noted in 9 (45%) patients including 2 patients with NPM1 mutated FLT 3 WT AML. 12 (60%) patients had secondary AML. The age unadjusted charlson comorbidity index (CCI) was 3 (2-9). 15 (75%) patients attained CR and 3 (15%) patients attained a CR with incomplete platelet recovery (CRp). CR +CRp rate was 90%. Two (10%) patients were refractory to induction and 5 (25%) patients relapsed at a later time point after induction. Median duration of hospital stay was 28 days (22-60). Median time to ANC &gt;1K was 23.5 days (18-29), excluding 2 patients who had refractory disease. Median time to platelet recovery &gt;100K was 25 days (20-44), excluding 2 patients with refractory disease and 3 patients with CRp. Regimen related toxicity included cardiac toxicity in 4 patients and bacteremia in 11 patients. Five (25%) patients were consolidated with stem cell transplant. Median overall survival (OS) was 151 days (38-1095) and progression free survival (PFS) was 131 days (38-1049). Conclusions: HiDAC/MITO induction is well tolerated by elderly patients with AML and demonstrates an overall response (CR+CRp) rate of 90% coupled with no induction deaths.
‘It's a traumatic illness, traumatic to witness’: a qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma
Authors: D. Orlowska, L.E. Selman, T. Beynon, E. Radcliffe, S. Whittaker, F. Child, R. Harding
Journal: British Journal of Dermatology (2018)

Cutaneous T-cell lymphomas (CTCL) are rare cancers, which can be difficult to diagnose, are incurable and adversely affect quality of life, particularly in advanced disease. Families often provide care, but little is known about their experiences or needs while caring for their relative with advanced disease or in bereavement.To explore the experiences of bereaved family caregivers of patients with CTCL.Single, semi-structured qualitative interviews were conducted with bereaved family caregivers of patients with CTCL recruited via a supra-regional CTCL clinic. Transcribed interviews were analysed thematically, focusing on advanced disease, the approach of death and bereavement.Fifteen carers of 11 deceased patients participated. Experiences clustered under four themes: (1) complexity of care and medical intervention; (2) caregiver roles in advanced CTCL; (3) person-centred vs. organization-centred care in advanced CTCL and (4) knowing and not knowing: reflections on dying, death and bereavement. Caregivers often had vivid recollections of the challenges of caring for their relative with advanced CTCL and some took on quasi-professional roles as a result. Advanced disease made high demands on both organizational flexibility and family resources. For many caregivers, seeing disease progression was a prolonged and profoundly traumatic experience. The extent to which they were prepared for their relative's death and supported in bereavement was highly variable. Sub-themes within each theme provide more detail about caregiver experiences.Family caregivers should be considered part of the wider healthcare team, acknowledging their multiple roles and the challenges they encounter in looking after their relative with CTCL as the disease progresses. Their experiences highlight the importance of organizational flexibility and of good communication between healthcare providers in advanced CTCL.
Abstract 14699: Epicardial Infarct Repair with a Novel Biologic Extracellular Matrix Improves Infarct Healing: Preclinical Validation
Authors: Holly E Mewhort, Jeannine D Turnbull, Jacqueline A Flewitt, H C Meijndert, David G Guzzardi, Daniyil A Svystonyuk, Christina Y Yang, Brodie D Lipon, Daniel S Park, Paul W Fedak
Journal: Circulation (2014)

BACKGROUND: Despite successful revascularization after MI, the extracellular matrix (ECM) continues to remodel resulting in cardiac fibrosis, LV dilatation and heart failure. We hypothesized that a...
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
Authors: Wenting Zheng, Carol E. O’Hear, Rajshekhar Alli, Jacob H. Basham, Hossam A. Abdelsamed, Lance E. Palmer, Lindsay L. Jones, Ben Youngblood, Terrence L. Geiger
Journal: Leukemia (2018)
Impact of working time restrictions on doctors’ training and patient care needs wider study
Authors: Matthew Limb
Journal: BMJ (2015)

More countries should collect data to compare how the European working time regulations affect the time that junior doctors spend on training and direct patient care, an academic has said.

Paul O’Connor is coauthor of a study led by the National University of Ireland, Galway, and published in the International Journal for Quality in Health Care .1 The study showed that interns in Ireland spent more time on direct patient care and educational activities and less time on indirect care activities than those in the United States or Australia. O’Connor told BMJ Careers that it was reassuring that the working time regulations did not seem to be having a negative impact …